[Advantages and prospects of the use of genetic vaccines for the protection from dangerous and socially significant infections].
Identifieur interne : 002007 ( Main/Exploration ); précédent : 002006; suivant : 002008[Advantages and prospects of the use of genetic vaccines for the protection from dangerous and socially significant infections].
Auteurs : I L Tutykhina ; D N Shcherbinin ; M M Shmarov ; D Iu Logunov ; B S NaroditskiSource :
- Vestnik Rossiiskoi akademii meditsinskikh nauk [ 0869-6047 ] ; 2011.
Descripteurs français
- KwdFr :
- Biodisponibilité, Contrôle des maladies contagieuses (), Contrôle des maladies contagieuses (tendances), Grippe humaine (), Grippe humaine (virologie), Humains, Immunisation passive (), Immunisation passive (tendances), Immunothérapie active (), Immunothérapie active (tendances), Prévision, Sous-type H5N1 du virus de la grippe A (génétique), Sous-type H5N1 du virus de la grippe A (immunologie), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (virologie), Vaccins à ADN (génétique), Vaccins à ADN (pharmacocinétique), Vaccins à virosomes (génétique), Vaccins à virosomes (pharmacocinétique), Virus du SRAS (génétique), Virus du SRAS (immunologie).
- MESH :
- génétique : Sous-type H5N1 du virus de la grippe A, Vaccins à ADN, Vaccins à virosomes, Virus du SRAS.
- immunologie : Sous-type H5N1 du virus de la grippe A, Virus du SRAS.
- pharmacocinétique : Vaccins à ADN, Vaccins à virosomes.
- tendances : Contrôle des maladies contagieuses, Immunisation passive, Immunothérapie active.
- virologie : Grippe humaine, Syndrome respiratoire aigu sévère.
- Biodisponibilité, Contrôle des maladies contagieuses, Grippe humaine, Humains, Immunisation passive, Immunothérapie active, Prévision, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Biological Availability, Communicable Disease Control (methods), Communicable Disease Control (trends), Forecasting, Humans, Immunization, Passive (methods), Immunization, Passive (trends), Immunotherapy, Active (methods), Immunotherapy, Active (trends), Influenza A Virus, H5N1 Subtype (genetics), Influenza A Virus, H5N1 Subtype (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Vaccines, DNA (genetics), Vaccines, DNA (pharmacokinetics), Vaccines, Virosome (genetics), Vaccines, Virosome (pharmacokinetics).
- MESH :
- chemical , genetics : Vaccines, DNA, Vaccines, Virosome.
- genetics : Influenza A Virus, H5N1 Subtype, SARS Virus.
- immunology : Influenza A Virus, H5N1 Subtype, SARS Virus.
- methods : Communicable Disease Control, Immunization, Passive, Immunotherapy, Active.
- chemical , pharmacokinetics : Vaccines, DNA, Vaccines, Virosome.
- prevention & control : Influenza, Human, Severe Acute Respiratory Syndrome.
- trends : Communicable Disease Control, Immunization, Passive, Immunotherapy, Active.
- virology : Influenza, Human, Severe Acute Respiratory Syndrome.
- Biological Availability, Forecasting, Humans.
Abstract
High frequency of epidemiological threats (H5N1 influenza, SARS, etc.) in modern world calls for the development of new flexible technologies for manufacturing efficacious vaccines and rapid reorientation of their production as appropriate. Genetic vaccination is one of such technologies aimed at prophylaxis of dangerous and socially significant infections. The technology is based on administration of one or several functionally active genes encoding for antigens of pathogens which induces formation of both cellular and humoral immunity against the respective microorganism. This property of genetic vaccines is used for the development of prophylactic schemes. New vaccines are currently being designed to prevent a variety of infections. The aim of the present review is to outline major trends in genetic vaccination leading to the improvement of its efficacy.
PubMed: 22168038
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001432
- to stream PubMed, to step Curation: 001432
- to stream PubMed, to step Checkpoint: 001401
- to stream Ncbi, to step Merge: 002428
- to stream Ncbi, to step Curation: 002428
- to stream Ncbi, to step Checkpoint: 002428
- to stream Main, to step Merge: 002031
- to stream Main, to step Curation: 002007
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Advantages and prospects of the use of genetic vaccines for the protection from dangerous and socially significant infections].</title><author><name sortKey="Tutykhina, I L" sort="Tutykhina, I L" uniqKey="Tutykhina I" first="I L" last="Tutykhina">I L Tutykhina</name></author><author><name sortKey="Shcherbinin, D N" sort="Shcherbinin, D N" uniqKey="Shcherbinin D" first="D N" last="Shcherbinin">D N Shcherbinin</name></author><author><name sortKey="Shmarov, M M" sort="Shmarov, M M" uniqKey="Shmarov M" first="M M" last="Shmarov">M M Shmarov</name></author><author><name sortKey="Logunov, D Iu" sort="Logunov, D Iu" uniqKey="Logunov D" first="D Iu" last="Logunov">D Iu Logunov</name></author><author><name sortKey="Naroditski, B S" sort="Naroditski, B S" uniqKey="Naroditski B" first="B S" last="Naroditski">B S Naroditski</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22168038</idno><idno type="pmid">22168038</idno><idno type="wicri:Area/PubMed/Corpus">001432</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001432</idno><idno type="wicri:Area/PubMed/Curation">001432</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001432</idno><idno type="wicri:Area/PubMed/Checkpoint">001401</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001401</idno><idno type="wicri:Area/Ncbi/Merge">002428</idno><idno type="wicri:Area/Ncbi/Curation">002428</idno><idno type="wicri:Area/Ncbi/Checkpoint">002428</idno><idno type="wicri:doubleKey">0869-6047:2011:Tutykhina I:advantages:and:prospects</idno><idno type="wicri:Area/Main/Merge">002031</idno><idno type="wicri:Area/Main/Curation">002007</idno><idno type="wicri:Area/Main/Exploration">002007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Advantages and prospects of the use of genetic vaccines for the protection from dangerous and socially significant infections].</title><author><name sortKey="Tutykhina, I L" sort="Tutykhina, I L" uniqKey="Tutykhina I" first="I L" last="Tutykhina">I L Tutykhina</name></author><author><name sortKey="Shcherbinin, D N" sort="Shcherbinin, D N" uniqKey="Shcherbinin D" first="D N" last="Shcherbinin">D N Shcherbinin</name></author><author><name sortKey="Shmarov, M M" sort="Shmarov, M M" uniqKey="Shmarov M" first="M M" last="Shmarov">M M Shmarov</name></author><author><name sortKey="Logunov, D Iu" sort="Logunov, D Iu" uniqKey="Logunov D" first="D Iu" last="Logunov">D Iu Logunov</name></author><author><name sortKey="Naroditski, B S" sort="Naroditski, B S" uniqKey="Naroditski B" first="B S" last="Naroditski">B S Naroditski</name></author></analytic><series><title level="j">Vestnik Rossiiskoi akademii meditsinskikh nauk</title><idno type="ISSN">0869-6047</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biological Availability</term><term>Communicable Disease Control (methods)</term><term>Communicable Disease Control (trends)</term><term>Forecasting</term><term>Humans</term><term>Immunization, Passive (methods)</term><term>Immunization, Passive (trends)</term><term>Immunotherapy, Active (methods)</term><term>Immunotherapy, Active (trends)</term><term>Influenza A Virus, H5N1 Subtype (genetics)</term><term>Influenza A Virus, H5N1 Subtype (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vaccines, DNA (genetics)</term><term>Vaccines, DNA (pharmacokinetics)</term><term>Vaccines, Virosome (genetics)</term><term>Vaccines, Virosome (pharmacokinetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Biodisponibilité</term><term>Contrôle des maladies contagieuses ()</term><term>Contrôle des maladies contagieuses (tendances)</term><term>Grippe humaine ()</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Immunisation passive ()</term><term>Immunisation passive (tendances)</term><term>Immunothérapie active ()</term><term>Immunothérapie active (tendances)</term><term>Prévision</term><term>Sous-type H5N1 du virus de la grippe A (génétique)</term><term>Sous-type H5N1 du virus de la grippe A (immunologie)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Vaccins à ADN (génétique)</term><term>Vaccins à ADN (pharmacocinétique)</term><term>Vaccins à virosomes (génétique)</term><term>Vaccins à virosomes (pharmacocinétique)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Vaccines, DNA</term><term>Vaccines, Virosome</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term><term>Vaccins à ADN</term><term>Vaccins à virosomes</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Communicable Disease Control</term><term>Immunization, Passive</term><term>Immunotherapy, Active</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Vaccins à ADN</term><term>Vaccins à virosomes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Vaccines, DNA</term><term>Vaccines, Virosome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Contrôle des maladies contagieuses</term><term>Immunisation passive</term><term>Immunothérapie active</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Communicable Disease Control</term><term>Immunization, Passive</term><term>Immunotherapy, Active</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Biological Availability</term><term>Forecasting</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Biodisponibilité</term><term>Contrôle des maladies contagieuses</term><term>Grippe humaine</term><term>Humains</term><term>Immunisation passive</term><term>Immunothérapie active</term><term>Prévision</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">High frequency of epidemiological threats (H5N1 influenza, SARS, etc.) in modern world calls for the development of new flexible technologies for manufacturing efficacious vaccines and rapid reorientation of their production as appropriate. Genetic vaccination is one of such technologies aimed at prophylaxis of dangerous and socially significant infections. The technology is based on administration of one or several functionally active genes encoding for antigens of pathogens which induces formation of both cellular and humoral immunity against the respective microorganism. This property of genetic vaccines is used for the development of prophylactic schemes. New vaccines are currently being designed to prevent a variety of infections. The aim of the present review is to outline major trends in genetic vaccination leading to the improvement of its efficacy.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Logunov, D Iu" sort="Logunov, D Iu" uniqKey="Logunov D" first="D Iu" last="Logunov">D Iu Logunov</name><name sortKey="Naroditski, B S" sort="Naroditski, B S" uniqKey="Naroditski B" first="B S" last="Naroditski">B S Naroditski</name><name sortKey="Shcherbinin, D N" sort="Shcherbinin, D N" uniqKey="Shcherbinin D" first="D N" last="Shcherbinin">D N Shcherbinin</name><name sortKey="Shmarov, M M" sort="Shmarov, M M" uniqKey="Shmarov M" first="M M" last="Shmarov">M M Shmarov</name><name sortKey="Tutykhina, I L" sort="Tutykhina, I L" uniqKey="Tutykhina I" first="I L" last="Tutykhina">I L Tutykhina</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002007 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002007 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22168038
|texte= [Advantages and prospects of the use of genetic vaccines for the protection from dangerous and socially significant infections].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22168038" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |